Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tacrolimus
Therapeutic Area : Immunology
Study Phase : Phase IV
Recipient : University Health Network, Toronto
Deal Size : Inapplicable
Deal Type : Inapplicable
Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 19, 2022
Lead Product(s) : Tacrolimus
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Recipient : University Health Network, Toronto
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tacrolimus
Therapeutic Area : Immunology
Study Phase : Phase IV
Recipient : University of British Columbia
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
October 22, 2021
Lead Product(s) : Tacrolimus
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Recipient : University of British Columbia
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apomorphine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Recipient : University of Calgary
Deal Size : Inapplicable
Deal Type : Inapplicable
Apomorphine Effects on Pain in Parkinson's Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 10, 2021
Lead Product(s) : Apomorphine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Recipient : University of Calgary
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abaloparatide
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Endo International
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada
Details : Endo obtained the rights to abaloparatide-subcutaneous injection and abaloparatide-transdermal patch, a novel formulation and route of administration currently undergoing clinical development. Endo, will be responsible for all commercial activities relat...
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
May 01, 2021
Lead Product(s) : Abaloparatide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Endo International
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Arfolitixorin,Fluorouracil,Oxaliplatin
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Isofol Medical
Deal Size : $100.0 million
Deal Type : Licensing Agreement
Isofol Announces Licensing Agreement for Paladin Labs Inc. To Commercialize Arfolitixorin in Canada
Details : The license agreement is initially focused on the development and commercialization of arfolitixorin as first-line treatment for metastatic colorectal cancer (mCRC) patients in Japan, which is projected to be the second largest addressable patient market...
Product Name : Modufolin
Product Type : Other Small Molecule
Upfront Cash : $103.0 million
February 11, 2020
Lead Product(s) : Arfolitixorin,Fluorouracil,Oxaliplatin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Isofol Medical
Deal Size : $100.0 million
Deal Type : Licensing Agreement